Real‐life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- 22 May 2017
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 90 (6) , 881-887
Abstract
Background: No previous studies have evaluated the performance of the Synergy stent in a large real‐life population.Objectives: To describe the initial real‐life experience with a novel everolimus eluting platinum chromium stent with abluminal biodegradable polymer (SYNERGY) in unselected patients from a nationwide registry.Methods: All implanted Synergy stents were compared with other new generation drug eluting stents (n‐DES) with >1,000 implantations in Sweden between March 2013 and October 2015. Restenosis, definite stent thrombosis (ST), myocardial infarction (MI) and death rates were assessed using propensity score and Cox regression analyses.Results: A total of 7,886 of Synergy stents and 64,429 other n‐DES (BioMatrix, N = 1,953; Orsiro, N = 4,946; Promus Element Plus, N= 2,543; Promus Premier, N= 20,414; Xience Xpedition, N= 7,971, Resolute/Resolute Integrity, N = 19,021; Ultimaster, N = 1,156; Resolute Onyx, N = 6,425) were implanted in 42,357 procedures.Restenosis and stent thrombosis occurred in 642 and 314 cases, respectively, in the overall population at 1 year. The cumulative rate of restenosis (1.1% vs. 1.0%, adjusted HR: 1.24 95% CI: 0.88–1.75; P = 0.21) and ST (0.4% vs. 0.5%, adjusted HR: 0.97; 95% CI: 0.63–1.50; P = 0.17) up to 1 year was low in both the Synergy group and the other n‐DES group. Death occurred in 5.2% versus 4.5% (adjusted HR: 1.14; 95% CI: 0.96–1.36; P = 0.11) and MI in 3.2% versus 3.5%, (adjusted HR: 1.11; 95% CI: 0.93–1.33; P = 0.24) up to 1 year.Conclusions: In a large real‐life population the Synergy stent appears to be safe and effective with a low rate of restenosis and ST comparable with other n‐DES.Keywords
This publication has 26 references indexed in Scilit:
- Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery DiseaseJACC: Cardiovascular Interventions, 2013
- A Prospective, Randomized Evaluation of a Novel Everolimus-Eluting Coronary StentJACC, 2011
- Stent Thrombosis in SwedenCirculation: Cardiovascular Interventions, 2009
- Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in SwedenNew England Journal of Medicine, 2009
- Differences in Restenosis Rate With Different Drug-Eluting Stents in Patients With and Without Diabetes MellitusJACC, 2009
- Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label CriteriaJACC, 2009
- Vascular Responses to Drug Eluting StentsArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in SwedenNew England Journal of Medicine, 2007
- Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable PolymerCirculation, 2004